Subject
Pharmacology,Immunology,Immunology and Allergy
Reference67 articles.
1. Bypassing anti-PD-(L) 1 therapy: Mechanisms and management strategies;Mortezaee;Biomed. Pharmacother.,2023
2. Association of B7–H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer;Altan;npj Breast Cancer,2018
3. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1–Negative Human Lung Cancers Heterogeneity of PD-L1, B7x, and HHLA2 in Lung Cancer;Cheng;Clin. Cancer Research,2018
4. B7–H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression;Lu;Oncogene,2022
5. The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy;John;Nat. Commun.,2022
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献